A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study

[1]  B. Astor,et al.  Association of Kidney Function With Anemia , 2013 .

[2]  A. Covic,et al.  Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  R. Garrick.  A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease , 2010 .

[4]  Ajay K. Singh.  Does TREAT give the boot to ESAs in the treatment of CKD anemia? , 2010, Journal of the American Society of Nephrology : JASN.

[5]  Troyen A. Brennan,et al.  The role of medical liability reform in federal health care reform. , 2009, The New England journal of medicine.

[6]  A. Vetter,et al.  Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. , 2009, Clinical nephrology.

[7]  M. Kinzig,et al.  Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. , 2009, International journal of clinical pharmacology and therapeutics.

[8]  M. Kinzig,et al.  Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial , 2009, BMC clinical pharmacology.

[9]  F. Locatelli,et al.  Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  Allen R Nissenson,et al.  Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2008, Kidney international.

[11]  Jocelyn E. Holden,et al.  Analyzing Change: A Primer on Multilevel Models with Applications to Nephrology , 2008, American Journal of Nephrology.

[12]  R. Foley,et al.  Hemoglobin level variability: associations with mortality. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[13]  Kdoqi.  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007 .

[14]  G. Eknoyan,et al.  Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[15]  L. Arab,et al.  Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  C. Jurkovitz,et al.  The epidemiology and control of anaemia among pre‐ESRD patients with chronic kidney disease , 2005, European journal of clinical investigation.

[17]  Madhumathi Rao,et al.  Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. , 2005, Kidney international.

[18]  K. Schulz,et al.  Multiplicity in randomised trials II: subgroup and interim analyses , 2005, The Lancet.

[19]  C. Wanner,et al.  Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  F. Port,et al.  Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  Alan Perkins,et al.  Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  S. Timmermans,et al.  The promises and pitfalls of evidence-based medicine. , 2005, Health affairs.

[23]  Francesco Locatelli,et al.  Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  F. Locatelli,et al.  Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  Robert A. Wolfe,et al.  DOPPS Estimates of Patient Life Years Attributable to Modifiable Hemodialysis Practices in the United States , 2004, Blood Purification.

[26]  R. Wolfe,et al.  Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  H. Feldman,et al.  Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  B. Astor,et al.  Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). , 2002, Archives of internal medicine.

[29]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  I. Macdougall,et al.  European best practice guidelines 5: target haemoglobin. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  E. Ku.  Pathophysiology of renal anemia. , 2000 .

[33]  K. Eckardt.  Pathophysiology of renal anemia. , 2000, Clinical nephrology.

[34]  N L Geller,et al.  Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. , 1987, Biometrics.